Covid Vaccine List UPSC | Corona Vaccines Development In India UPSC – The Government of India launched the ‘Mission COVID Suraksha’, a development program for Indian candidates and researchers working on the COVID-19 vaccine. Under this mission, the Government would facilitate the clinical development, manufacturing and licensing of Indian vaccines to curb the virus attack.
Candidates preparing for the IAS Exam can expect questions based on the Novel Coronavirus, its vaccines, affects, etc. in the GS-2 and GS-3 paper under Government Policies, welfare schemes, Science and Technology, and Indian achievements part of the paper.
What is Mission COVID Suraksha?
- The Government of India has sanctioned Rs.900 crores for the Phase I of the Mission COVID Suraksha, for a period of 12 months
- This mission will accelerate the development of approximately 5-6 vaccines for coronavirus. However, a total of 10 vaccine candidates have been supported by DBT till now
- Complete focus on the preclinical and clinical development of the vaccine is to be taken care of, for quick release and to restrict any further spread of the Novel coronavirus in the country
- With an end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment, would consolidate all available and funded resources towards an accelerated product development
- The grant for Research and Development (R&D) of the Indian COVID-19 vaccine will be provided by the Department of Biotechnology (DBT)
- It will be implemented by a dedicated Mission Implementation Unit at the Biotechnology Industry Research Assistance Council (BIRAC)
Objectives of Mission COVID Suraksha
The main objectives of this mission include:
- Funding the candidate vaccines with their testing, manufacturing, licensing, and distribution in the market
- Establishing clinical trial sites, strengthening the existing laboratories, and assisting with the internal and external quality management system
- Supporting the development of common harmonized protocols, training, data management systems, and regulatory submissions
- Capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials will also be supported under the Mission
- The development of a suitable Target Product Profile is another key element of the mission. This will ensure that the vaccines being introduced through the mission have preferred characteristics applicable to India
Ravi Agrahari Science And Technology Book Pdf UPSC Eng & Hindi
Covid Vaccine List UPSC | Corona Vaccines Development In India UPSC
Vaccine | Country |
Sputnik V | Russia |
Pfizer–BioNTech | Multinational |
Oxford–AstraZeneca | Multinational |
United States | |
BBIBP-CorV | Multinational |
CoronaVac | Brazil |
Chile | |
Novavax | United Kingdom |
South Africa | |
Johnson & Johnson | Multinational |
United States | |
Brazil | |
South Africa | |
Covaxin | India |
Convidecia | Multinational |
Moderna | United States |
Apart from the ones mentioned above, a few other COVID-19 vaccine candidates which have not been very successful have been given below:
- AZD1222 by University of Oxford
- Ad5-nCoV by Beijing Institute of Biotechnology
- Ad26.COV2.S by Johnson & Johnson
- CoVLPs by Government of Canada and Quebec
For More Latest Updated about Covid -19 Visit WHO Offiicial Website –